IGF1 and prostate carcinoma: Although there were no interactions detected between serum 25(OH)D and IGF analytes when considering combined treatment arms, 25(OH)D was associated with an increased risk of prostate cancer in the presence of higher serum IGF-2 (≥1707.59 ng/mL) in the placebo arm of the trial.